FXR signaling in metabolic disease
- 20 November 2007
- journal article
- review article
- Published by Wiley in FEBS Letters
- Vol. 582 (1) , 10-18
- https://doi.org/10.1016/j.febslet.2007.11.015
Abstract
Farnesoid X receptor (FXR), a member of the nuclear receptor superfamily, has been shown to be important in controlling numerous metabolic pathways; these include roles in maintaining bile acid, lipid and glucose homeostasis, in preventing intestinal bacterial infection and gallstone formation and in modulating liver regeneration and tumorigenesis. The accumulating data suggest that FXR may be a pharmaceutical target for the treatment of certain metabolic diseases.Keywords
This publication has 77 references indexed in Scilit:
- Effects of FXR in foam-cell formation and atherosclerosis developmentBiochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2006
- Spontaneous hepatocarcinogenesis in farnesoid X receptor-null miceCarcinogenesis: Integrative Cancer Research, 2006
- Nuclear bile acid receptor FXR as pharmacological target: Are we there yet?FEBS Letters, 2006
- Benefit of farnesoid X receptor inhibition in obstructive cholestasisProceedings of the National Academy of Sciences, 2006
- FXR: a target for cholestatic syndromes?Emerging Therapeutic Targets, 2006
- Transient impairment of the adaptive response to fasting in FXR‐deficient miceFEBS Letters, 2005
- TRRAP as a hepatic coactivator of LXR and FXR functionBiochemical and Biophysical Research Communications, 2005
- The Enzymes, Regulation, and Genetics of Bile Acid SynthesisAnnual Review of Biochemistry, 2003
- The RXR heterodimers and orphan receptorsPublished by Elsevier ,1995
- The Role of Bile and Bile Acids in Bacterial Translocation in Obstructive Jaundice in RatsEuropean Surgical Research, 1993